These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 23783081)

  • 1. A phase III single arm, multicenter, open-label study to assess the immunogenicity and tolerability of a pentavalent DTwP-HepB-Hib vaccine in indian infants.
    Eregowda A; Lalwani S; Chatterjee S; Vakil H; Ahmed K; Costantini M; Lattanzi M
    Hum Vaccin Immunother; 2013 Sep; 9(9):1903-9. PubMed ID: 23783081
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lot-to-lot consistency study of the fully liquid pentavalent DTwP-HepB-Hib vaccine Quinvaxem (®) demonstrating clinical equivalence, suitability of the vaccine as a booster and concomitant administration with measles vaccine.
    Aspinall S; Traynor D; Bedford P; Hartmann K
    Hum Vaccin Immunother; 2012 Aug; 8(8):1109-18. PubMed ID: 22854660
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and immunogenicity of a toddler dose following an infant series of a hexavalent diphtheria, tetanus, acellular pertussis, inactivated poliovirus, Haemophilus influenzae type b, hepatitis B vaccine administered concurrently or at separate visits with a heptavalent pneumococcal conjugate vaccine.
    Halperin SA; Tapiéro B; Dionne M; Meekison W; Diaz-Mitoma F; Zickler P; Rubin E; Embree J; Bhuyan P; Lee A; Li M; Tomovici A
    Pediatr Infect Dis J; 2014 Jan; 33(1):73-80. PubMed ID: 24346596
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety, immune lot-to-lot consistency and non-inferiority of a fully liquid pentavalent DTwp-HepB-Hib vaccine in healthy Indian toddlers and infants.
    Gandhi DJ; Dhaded SM; Ravi MD; Dubey AP; Kundu R; Lalwani SK; Chhatwal J; Mathew LG; Gupta M; Sharma SD; Bavdekar SB; Jayanth MV; Ravinuthala S; Sil A; Dhingra MS
    Hum Vaccin Immunother; 2016 Apr; 12(4):946-54. PubMed ID: 26580093
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunogenicity and safety of an indigenously manufactured reconstituted pentavalent (DTwP-HBV+Hib) vaccine in comparison with a foreign competitor following primary and booster immunization in Indian children.
    Sharma HJ; Yadav S; Lalwani SK; Kapre SV; Jadhav SS; Chakravarty A; Parekh SS; Palkar S; Bhardwaj SH; Namjoshi GS; Verma V
    Hum Vaccin; 2011 Apr; 7(4):451-7. PubMed ID: 21403463
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of prophylactic or therapeutic administration of paracetamol on immune response to DTwP-HepB-Hib combination vaccine in Indian infants.
    Sil A; Ravi MD; Patnaik BN; Dhingra MS; Dupuy M; Gandhi DJ; Dhaded SM; Dubey AP; Kundu R; Lalwani SK; Chhatwal J; Mathew LG; Gupta M; Sharma SD; Bavdekar SB; Rout SP; Jayanth MV; D'Cor NA; Mangarule SA; Ravinuthala S; Reddy E J
    Vaccine; 2017 May; 35(22):2999-3006. PubMed ID: 28449972
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized, controlled trial to assess the immunogenicity and safety of a heptavalent diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, hib and meningococcal serogroup C combination vaccine administered at 2, 3, 4 and 12-18 months of age.
    Szenborn L; Czajka H; Brzostek J; Konior R; Caubet M; Ulianov L; Leyssen M
    Pediatr Infect Dis J; 2013 Jul; 32(7):777-85. PubMed ID: 23838777
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and immunogenicity of a new fully liquid DTPw-HepB-Hib combination vaccine in infants.
    Kanra G; Kara A; Demiralp O; Contorni M; Hilbert AK; Spyr C; Viviani S
    Hum Vaccin; 2006; 2(4):155-60. PubMed ID: 17012890
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenicity and reactogenicity of a combined fully liquid DTPw-HepB-Hib pentavalent vaccine in healthy infants: no clinically relevant impact of a birth dose of hepatitis B vaccine.
    Gentile A; Umido V; Czerniuk P; Nacul J; Seigelchifer M; Hilbert AK; Yela U; Herzog C; Aeberhard U; Spyr C
    Int J Infect Dis; 2011 Jan; 15(1):e24-9. PubMed ID: 21093342
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogenicity and safety of 3-dose primary vaccination with combined DTPa-HBV-IPV/Hib in Indian infants.
    Lalwani SK; Agarkhedkar S; Sundaram B; Mahantashetti NS; Malshe N; Agarkhedkar S; Van Der Meeren O; Mehta S; Karkada N; Han HH; Mesaros N
    Hum Vaccin Immunother; 2017 Jan; 13(1):120-127. PubMed ID: 27629913
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A fully liquid DTPw-HepB-Hib combination vaccine for booster vaccination of toddlers in El Salvador.
    Suárez E; Asturias EJ; Hilbert AK; Herzog C; Aeberhard U; Spyr C
    Rev Panam Salud Publica; 2010 Feb; 27(2):117-24. PubMed ID: 20339615
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenicity and safety of primary and booster vaccination with 2 investigational formulations of diphtheria, tetanus and Haemophilus influenzae type b antigens in a hexavalent DTPa-HBV-IPV/Hib combination vaccine in comparison with the licensed Infanrix hexa.
    Vesikari T; Rivera L; Korhonen T; Ahonen A; Cheuvart B; Hezareh M; Janssens W; Mesaros N
    Hum Vaccin Immunother; 2017 Jul; 13(7):1505-1515. PubMed ID: 28340322
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and immunogenicity of a new formulation of a pentavalent DTwP-HepB-Hib vaccine in healthy Indian infants-A randomized study.
    Aloysia D'Cor N; Siddaiah P; Mohapatra S; Dhaded SM; I V P; Kar S; V N T; Muley P; Chhatwal J; Patnaik BN; Vidor E; Moureau A; Patel DM; Midde VJ; Jagga SR; Peesapati S; Noriega F
    PLoS One; 2023; 18(8):e0284898. PubMed ID: 37582114
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the reactogenicity and immunogenicity of a combined diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated polio (DTPa-HBV-IPV) vaccine, mixed with the Haemophilus influenzae type b (Hib) conjugate vaccine and administered as a single injection, with the DTPa-IPV/Hib and hepatitis B vaccines administered in two simultaneous injections to infants at 2, 4 and 6 months of age.
    Arístegui J; Dal-Ré R; Díez-Delgado J; Marés J; Casanovas JM; García-Corbeira P; De Frutos E; Van Esso D; Verdaguer J; De la Flor J; Moraga F; Boceta R; García-Martínez JA
    Vaccine; 2003 Sep; 21(25-26):3593-600. PubMed ID: 12922087
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparative clinical study to assess safety and reactogenicity of a DTwP-HepB+Hib vaccine.
    Dalvi S; Kulkarni PS; Phadke MA; More SS; Lalwani SK; Jain D; Manglani M; Garg BS; Doibale MK; Deshmukh CT;
    Hum Vaccin Immunother; 2015; 11(4):901-7. PubMed ID: 25933183
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A multicenter, prospective, open-label, non-comparative study to evaluate the immunogenicity and tolerance of a new, fully liquid pentavalent vaccine (DTwP-HepB-Hib vaccine).
    Ali SS; Chandrashekar SR; Singh M; Bansal RK; Sharma DR; Arora D
    Hum Vaccin; 2007; 3(4):116-20. PubMed ID: 17617743
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibody persistence of two pentavalent DTwP-HB-Hib vaccines to the age of 15-18 months, and response to the booster dose of quadrivalent DTwP-Hib vaccine.
    Sharma H; Yadav S; Lalwani S; Kapre S; Jadhav S; Parekh S; Palkar S; Ravetkar S; Bahl S; Kumar R; Shewale S
    Vaccine; 2013 Jan; 31(3):444-7. PubMed ID: 23196204
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The immunogenicity and safety of a reduced PRP-content DTPw-HBV/Hib vaccine when administered according to the accelerated EPI schedule.
    Chatterjee S; Rego SJ; D'Souza F; Bhatia BD; Collard A; Datta SK; Jacquet JM
    BMC Infect Dis; 2010 Oct; 10():298. PubMed ID: 20950457
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interchangeability of Quinvaxem during primary vaccination schedules: results from a phase IV, single-blind, randomized, controlled, single-center, non-inferiority study.
    Capeding MR; Jica C; Macura-Biegun A; Rauscher M; Alberto E
    Vaccine; 2014 Feb; 32(7):888-94. PubMed ID: 24176498
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogenicity and safety of a new hexavalent vaccine (DTaP5-IPV-HB-Hib) administered in a mixed primary series schedule with a pentavalent vaccine (DTaP5-IPV-Hib).
    Martinón-Torres F; Boisnard F; Thomas S; Sadorge C; Borrow R;
    Vaccine; 2017 Jun; 35(30):3764-3772. PubMed ID: 28583305
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.